Cargando…
Diseases Linked to Polypharmacy in Elderly Patients
INTRODUCTION: Polypharmacy in several cases is deemed necessary and elderly patients are prone to this phenomenon. The objective of this study was to identify the prevalence and the predictors of polypharmacy among consecutively unplanned admissions of patients aged ≥65 years. PATIENTS AND METHODS:...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5757103/ https://www.ncbi.nlm.nih.gov/pubmed/29434639 http://dx.doi.org/10.1155/2017/4276047 |
_version_ | 1783290803538362368 |
---|---|
author | Vrettos, Ioannis Voukelatou, Panagiota Katsoras, Apostolos Theotoka, Despoina Kalliakmanis, Andreas |
author_facet | Vrettos, Ioannis Voukelatou, Panagiota Katsoras, Apostolos Theotoka, Despoina Kalliakmanis, Andreas |
author_sort | Vrettos, Ioannis |
collection | PubMed |
description | INTRODUCTION: Polypharmacy in several cases is deemed necessary and elderly patients are prone to this phenomenon. The objective of this study was to identify the prevalence and the predictors of polypharmacy among consecutively unplanned admissions of patients aged ≥65 years. PATIENTS AND METHODS: In 310 patients (51% women), mean age 80.24 years (95% CI 79.35–81.10), demographic characteristics, medical history, medications, and cause of admission were recorded. Parametric tests and multiple logistic regression analysis were applied to identify the factors that have significant association with polypharmacy. RESULTS: 53.5% of patients belonged to polypharmacy group. In multivariate analysis the independent predictors of polypharmacy were arterial hypertension (p = 0.003, OR = 2.708, and 95% CI 1.400–5.238), coronary artery disease (p = 0.001, OR = 8.274, and 95% CI 3.161–21.656), heart failure (p = 0.030, OR = 4.042, and 95% CI 1.145–14.270), atrial fibrillation (p = 0.031, OR = 2.477, and 95% CI 1.086–5.648), diabetes mellitus (p = 0.010, OR = 2.390, and 95% CI 1.232–4.636), dementia (p = 0.001, OR = 4.637, and 95% CI 1.876–11.464), and COPD (p = 0.022, OR = 3.626, and 95% CI 1.208–10.891). CONCLUSIONS: Polypharmacy mainly was linked to cardiovascular diseases. If deprescribing is not feasible, physicians must oversee those patients in order to recognise early, possible drug reactions. |
format | Online Article Text |
id | pubmed-5757103 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-57571032018-02-12 Diseases Linked to Polypharmacy in Elderly Patients Vrettos, Ioannis Voukelatou, Panagiota Katsoras, Apostolos Theotoka, Despoina Kalliakmanis, Andreas Curr Gerontol Geriatr Res Research Article INTRODUCTION: Polypharmacy in several cases is deemed necessary and elderly patients are prone to this phenomenon. The objective of this study was to identify the prevalence and the predictors of polypharmacy among consecutively unplanned admissions of patients aged ≥65 years. PATIENTS AND METHODS: In 310 patients (51% women), mean age 80.24 years (95% CI 79.35–81.10), demographic characteristics, medical history, medications, and cause of admission were recorded. Parametric tests and multiple logistic regression analysis were applied to identify the factors that have significant association with polypharmacy. RESULTS: 53.5% of patients belonged to polypharmacy group. In multivariate analysis the independent predictors of polypharmacy were arterial hypertension (p = 0.003, OR = 2.708, and 95% CI 1.400–5.238), coronary artery disease (p = 0.001, OR = 8.274, and 95% CI 3.161–21.656), heart failure (p = 0.030, OR = 4.042, and 95% CI 1.145–14.270), atrial fibrillation (p = 0.031, OR = 2.477, and 95% CI 1.086–5.648), diabetes mellitus (p = 0.010, OR = 2.390, and 95% CI 1.232–4.636), dementia (p = 0.001, OR = 4.637, and 95% CI 1.876–11.464), and COPD (p = 0.022, OR = 3.626, and 95% CI 1.208–10.891). CONCLUSIONS: Polypharmacy mainly was linked to cardiovascular diseases. If deprescribing is not feasible, physicians must oversee those patients in order to recognise early, possible drug reactions. Hindawi 2017 2017-12-25 /pmc/articles/PMC5757103/ /pubmed/29434639 http://dx.doi.org/10.1155/2017/4276047 Text en Copyright © 2017 Ioannis Vrettos et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Vrettos, Ioannis Voukelatou, Panagiota Katsoras, Apostolos Theotoka, Despoina Kalliakmanis, Andreas Diseases Linked to Polypharmacy in Elderly Patients |
title | Diseases Linked to Polypharmacy in Elderly Patients |
title_full | Diseases Linked to Polypharmacy in Elderly Patients |
title_fullStr | Diseases Linked to Polypharmacy in Elderly Patients |
title_full_unstemmed | Diseases Linked to Polypharmacy in Elderly Patients |
title_short | Diseases Linked to Polypharmacy in Elderly Patients |
title_sort | diseases linked to polypharmacy in elderly patients |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5757103/ https://www.ncbi.nlm.nih.gov/pubmed/29434639 http://dx.doi.org/10.1155/2017/4276047 |
work_keys_str_mv | AT vrettosioannis diseaseslinkedtopolypharmacyinelderlypatients AT voukelatoupanagiota diseaseslinkedtopolypharmacyinelderlypatients AT katsorasapostolos diseaseslinkedtopolypharmacyinelderlypatients AT theotokadespoina diseaseslinkedtopolypharmacyinelderlypatients AT kalliakmanisandreas diseaseslinkedtopolypharmacyinelderlypatients |